The combined capital raise and merger transform Jasper's balance sheet and pipeline, likely driving near-term momentum on the cash infusion. However, the extreme dilution — particularly the convertible preferred conversion — will cap upside for common shareholders. Monitor the stockholder vote on the preferred conversion proposal and any early CVR milestone events for briquilimab.
Price Chart
Executive Summary
Jasper Therapeutics entered into a definitive merger agreement to acquire Kira Pharmaceuticals, with Kira shareholders receiving up to 5.6M shares of Jasper common stock and convertible preferred shares (valued at a $150M company valuation). Concurrently, Jasper raised $132M in a PIPE through the sale of convertible preferred stock to investors. Existing Jasper common stockholders will receive one contingent value right (CVR) per share, entitling them to a potential $30M lump-sum payment if the FDA issues a priority review voucher for briquilimab by December 31, 2028. The transactions are transformative for the micro-cap biotech, providing deep funding and a new pipeline, but the combined issuance of stock and convertible securities represents massive dilution to current shareholders.
Key Financial Metrics
Key Facts
- Merger agreement with Kira Pharmaceuticals at a $150M company valuation; Kira shareholders receive up to 5,587,800 shares of Jasper common stock and up to 4,996,178 shares of Jasper convertible preferred stock (plus 254,462 shares for SAFE holders).
- Concurrent $132M PIPE from institutional investors purchasing 4,655,951 shares of non-voting convertible preferred stock.
- Existing Jasper common shareholders receive one CVR per share, potentially paying $30M if an FDA priority review voucher for briquilimab is issued by Dec 31, 2028.
- Lock-up agreements of 180 days for all directors and executive officers of both Jasper and Kira.
- Post-closing board will have 6 members: 5 from Jasper and 1 from Kira (Patrick Crutcher).
- Jasper's outstanding common stock as of July 16, 2026: 28,079,552 shares.
Financial Impact
The PIPE ($132M) is ~6x Jasper's pre-merger market cap of $22M. The merger consideration could add up to 5.6M common shares (19.9% of pre-merger total) plus convertible preferred that can convert into ~284M common shares (if full conversion under 61:1 ratio and shareholder approval obtained). The net effect is massive dilution, offset by significant cash infusion.
Risk Factors
- Massive equity dilution from the PIPE and merger consideration; existing shareholders' stake is heavily reduced.
- CVR milestone may never be achieved (FDA priority review voucher not guaranteed), rendering the CVR worthless.
- Integration risk between Jasper and Kira; combined entity may face operational challenges.
- Shareholder approval required for preferred stock conversion; rejection could limit upside for PIPE investors.
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 3 SEC documents filed with EDGAR.
| Document | Accession Number |
|---|---|
| 8-K Filing (Primary) | 0001213900-26-078887 |
| Document: ea029822901ex10-1.htm | 0001213900-26-078887 |
| Document: ea029822901ex10-2.htm | 0001213900-26-078887 |
Filters
| Type | Now | ||||
|---|---|---|---|---|---|
Oct 23, 2026 3d ago | SC TO-I/A | $0.5100 | awaiting T+5 | — | $0.5050 (−0.98%) |
Oct 20, 2026 6d ago | DEF 14A | $0.4999 | awaiting T+5 | — | $0.5050 (+1.02%) |
Oct 15, 2026 11d ago | 8-K | $0.5321 $0.4956 | ▼ −6.86% | ▼ −5.85% | $0.5050 (−5.09%) |
Oct 15, 2026 11d ago | Press Release | $0.5320 $0.4960 | ▲ +6.77% | ▲ +5.75% | $0.5050 (+5.08%) |
Oct 14, 2026 12d ago | S-3 | $0.5321 $0.4956 | ▲ +6.86% | ▲ +5.85% | $0.5050 (+5.09%) |
Oct 7, 2026 19d ago | 8-K | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Oct 7, 2026 19d ago | SC TO-I | $0.5697 $0.5010 | ▼ −12.06% | ▼ −11.08% | $0.5050 (−11.36%) |
Sep 24, 2026 4w ago | 25-NSE | $0.6091 $0.5652 | ▲ +7.21% | ▲ +6.99% | $0.5050 (+17.09%) |
Aug 14, 2026 10w ago | Press Release | $0.7901 $0.7160 | ▼ −9.38% | ▼ −8.01% | $0.5050 (−36.08%) |
Jul 31, 2026 12w ago | 8-K | $0.6300 $0.7095 | ▲ +12.62% | ▲ +9.11% | $0.5050 (−19.84%) |
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers